Precision Biologics’ New Antibody Targets Tumor Activity in Ovarian, Other Cancer Cells

Precision Biologics’ New Antibody Targets Tumor Activity in Ovarian, Other Cancer Cells
Dallas-based Precision Biologics says its new antibody targets tumor cells expressing the NEO-201 neo-antigen, which are present in ovarian and gastrointestinal cancers. The company presented new preclinical data earlier this month at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, D.C. The findings revealed that the new monoclonal antibody can induce potent immune responses against NEO-201-positive tumor cells, leaving healthy cells unharmed. Data also showed that it works in synergy with NantKwest's off-the-shelf natural killer cells. Kristen Zeligs, MD, of the Walter Reed National Military Medical Center in Bethesda, Md., presented the abstract, "Preclinical characterization of a novel monoclonal antibody targeting a neo-antigen expressed in ovarian and GI malignancies," on April 3. “Precision Biologics continues to make progress with our preclinical and clinical programs,” the company's president and CEO, Philip M. Arlen, said in a press release. “As this study demonstrates, our novel, humanized IgG1 monoclonal antibody, NEO-201, specifically targets a neoantigen expressed on a broad range of solid tumors. Tumor cell killing, antibody-dependent, cell-mediated cytotoxicity (ADCC), was significantly enhanced when NEO-201 was combined with an allogenic source of natural killer cells provided by NantKwest.” As a result of high mutational load, cancer cells offer exhibit proteins with different sequence or conformation that can be recognized by the immune system as harmful. In scientific language, these proteins are usually called neo-antigens. Precision Biologics has developed a novel antibody targeting the neo-antigen NEO-201, commonly found in ovarian and cancers from the gastrointestinal tract. Da
Subscribe or to access all post and page content.